Abstract. Expression of MIR125A is diminished in breast tumors, however the reason for the hsa-mir-125a decrease in the cancer is not known. HER2 is encoded by ERBB2, a target for hsa-miR-125a which interacts with the 3'UTR of ERBB2 mRNA. The present study reveals that a polymorphism (rs12976445) within the pri-miR-125a sequence correlates with the amount of mature hsa-miR-125a in breast tumor samples. miRNA, RNA and DNA were extracted from breast cancer samples obtained from 26 patients. Following immunohistological evaluation of the samples, the ERBB2, PGR and ESR1 mRNA profiles were also analyzed using real-time PCR. Genomic DNA was sequenced using MIR125A flanking primers. PCR products were analyzed using a BaeGI restriction enzyme specific to the rs12976445 variant. The rs12976445 variant (C/T and C/C) correlated with a lower level of hsa-miR-125a in comparison with the T/T variant. The expression of HER2 mRNA was increased in tumors with the rs12976445 variant (C/T and C/C) compared with T/T. We conclude that rs12976445 may be a potential prognostic marker of HER2 expression in breast cancer. Its predictive value on the efficacy of trastuzumab treatment in patients with HER2-positive breast cancer warrants further study.
Introduction
The MIR125A gene is located on chromosome 19 in a cluster with MIR99B and MIR7E. Mature hsa-miR-125a interacts with a conserved 8-nt binding element, CUCAGGGA, located within the proximal 3'-UTR of ERBB2 and is able to bifunctionally mediate ERBB2 transcript decay and translational inhibition (1) . Besides ERBB2, HuR, Rock-1, KLF13 and ARID3B mRNA levels are also diminished by hsa-miR-125a (2, 3) . Decreased levels of hsa-miR-125a have been detected in breast cancer and gastric cancer (4, 5) . Furthermore, increased levels of miR-125 in breast cancer cells inhibit cell growth via the suppression of cell proliferation and by promotion of apoptosis (6) . In the nucleus, pri-miR-125a is transformed into mature hsa-miR-125a by the Drosha system (7) . This process is obstructed by estrogen receptor (ER) α (8) . Germline mutations in BRCA1/2, ATM, PTEN and CHEK2 are common in familial breast cancer, but they explain only one-quarter of the familial risk (9) . Thus, it is likely that there are a number of unidentified genes which contain loci encoding miRNAs that confer susceptibility to breast cancer. An SNP (rs12975333) has been observed in the hsa-miR-125a miRNA precursor sequence, which blocks the pri-to pre-miR-125a processing step (10) .
In our study, we hypothesized that three other known genetic variants of pri-miR-125a (rs10404453, rs12976445 and rs143525573) should correlate with levels of mature hsa-miR-125a in breast cancer cells. Consequently, ERBB2 mRNA levels would be increased in breast tumors with these genetic variants, suggesting that genetic variants that influence hsa-miR-125a expression have potential as genetic markers of breast cancer. In particular, these variants may have predictive value in designing treatment with drugs against HER2.
Materials and methods
Patients and samples. Tissue samples were obtained from 26 Polish patients undergoing surgery for breast cancer in the Department of Surgery, Chair of Oncology of Poznan University of Medical Sciences (PUMS; see Table I for patient and tumor characteristics). No preoperative radiotherapy or chemotherapy was used. The study protocol was approved by the bioethics board of PUMS. Tumor tissue and blood samples for comprehensive experiments were collected after obtaining written informed consent from all participants.
Immediately after surgery, the tissue samples were stored in liquid nitrogen. PCR, sequencing and restriction analysis. DNA specimens were amplified using standard PCR protocols. The PCR primers corresponding to pri-pre-miR-125a used for MIR125A sequencing were: 5'-TTTTGGTCTTTCTGTCTCTGG-3' and 5'-TGGAGGAAGGGTATGAGGAGT-3'. The PCR products were purified with the Gel-out purification kit (A&A Biotechnology, Gdynia, Poland) and sequenced at the DNA Sequencing and Oligonucleotide Synthesis Laboratory of the Institute of Biochemistry and Biophysics of the Polish Academy of Sciences (Warsaw, Poland). The sequencing results were analyzed using BioEdit Sequence Alignment Editor. In addition to sequencing, the SNP (rs12976445) was genotyped using the restriction enzyme BaeGI (New England Biolabs, Ipswich, MA, USA). All results were in agreement.
Real-time PCR. To evaluate the MIR125A expression level, TaqMan microRNA Assays (Life Technologies) for real-time RT-PCR were used. Similar assays were also used for hsa-miR-206, hsa-miR-125b, hsa-miR-17 and hsa-miR-27b; U6 RNA was used as a reference gene. All samples were reverse transcribed using the TaqMan MicroRNA Reverse Transcription kit and specific starters from the TaqMan microRNA Assay. TaqMan Universal PCR Master Mix and specific primers from TaqMan microRNA Assays were used to quantify the samples in a Roche (Indianapolis, IN, USA) LC 480 cycler. The relative amounts of all miRNAs were calculated using standard curves and compared as ratios using the U6 reference gene.
ERBB2, ESR1 and PGR mRNA levels were analyzed by reverse transcription (Life Technologies) and TaqMan real-time PCR (Roche). HMBS and POL2 were used as reference genes.
Statistical analysis. Statistical analysis was conducted using Instat software. P≤0.05 was considered to indicate statistically significant differences. A t-test was used to compare the differences in mean expression levels between the groups of samples from the real-time RT-PCR experiment. The mean of the log 10 of the ratio between target gene expression levels and reference gene expression levels was also calculated.
Results

Frequency of the rs12976445 variant.
A total of 26 surgically removed breast tumors were analyzed with the aim of identifying genetic polymorphisms in the gene encoding hsa-miR-125a. Of the samples, 21 were congealed in liquid nitrogen and 5 were paraffin-embedded archival samples. The group of 26 samples was analyzed routinely using histopathological methods. The patients were classified by the TNM system and the samples were also grouped into ER, PR and HER positive and negative cases. The results are presented in Table I . DNA extracted from the samples was amplified using primers spanning pri-, pre-and mature hsa-miR-125a. There are four known SNPs in the amplified fragment of MIR125A: rs12976445, rs10404453, rs12975333 and rs143525573 (11) . Subsequently all amplicons from the tumor samples were sequenced. A single nucleotide change from T to C (variant rs12976445) was identified in the sequence of pri-miR-125 in the breast cancer patients (15 nucleotides downstream from the start of pri-miR-125a, 54 nucleotides upstream from the start of pre-miR-125, 68 nucleotides upstream of the miR-125a-5p). The three other variants were not present in these samples. To confirm the results of the MIR125A sequencing and to establish the frequency of the variant, the DNA extracted from the congealed tumors and paraffin-embedded tissues was amplified using the same pair of primers as for the sequencing. Subsequently the products were digested using the restriction enzyme BaeGI (GKGCM^C). The restriction analysis revealed that 8 out of 26 patients were T/T homozygotes (30.8%), 15 (57.7%) were T/C heterozygotes and 3 were C/C homozygotes (11.5%; Fig. 1 ). For 14 tumors, corresponding blood samples were available and the same genetic variant was investigated using restriction analysis with BaeGI (Fig. 1B) . The results revealed exactly the same distribution of variants in the blood as in the corresponding tumors.
MiRNA level. The expression of MIR125A was analyzed in the tumours using real-time PCR (Fig. 2) . The hsa-miR-125a level was decreased by 85% (P=0.024) in the samples with the variants CC and CT, compared with the TT variant. When the T homozygous variant, heterozygotoes and the C homozygotes were compared, a gradual decrease of hsa-miR-125a levels was observed. In the present samples, no correlation was observed between the expression of hsa-miR-125b, hsa-miR-27, hsa-miR-17-5 or hsa-miR-206 and the rs12976445 variant. mRNA of the ERBB2 gene was increased by 2.4-fold (P=0.044) in the tumor samples with the variant C/C and C/T MIR125A variants, compared with the T/T variant. ESR1 and PGR mRNA levels did not correlate with the rs12976445 variant.
These findings suggest that the ERBB2 mRNA increase may be caused by diminished levels of inhibitory hsa-miR-125a.
Discussion
The present study shows that in breast cancers the rs12976445 variant (in the T/C and C/C types as opposed to the T/T type) located in pri-hsa-miR-125a correlated with lower levels of hsa-miR-125a and that the mRNA levels of ERBB2 were increased. ERBB2 encodes the HER2 breast cancer marker gene. The normal HER2 level, designated 0, may be increased and so is measured by histopathological methods which allocate results to a scale from 1 to 3. The scale is used to test whether it may be possible to treat the patient with trastuzumab (12) .
Deregulation of ERBB2 and ERBB3, singly or in combination, is able to induce malignant transformation. Of all human breast cancers, ~25% are associated with amplification and overexpression of ERBB2. In particular, overexpression of ERBB2 drives cell survival, proliferation, motility and the invasion mechanisms characteristic of this aggressive form of human breast cancer (1) .
Decreased levels of hsa-miR-125a were observed in correlation with the rs12976445 variant. Similar results were described by Hu et al in correlation with recurrent pregnancy loss (13) . For the first time, the present study shows the correlation between the rs12976445 variant (T/C and C/C) and miR-125 levels in breast tumors. The rs12976445 variant is located in the pri-miR-125a sequence and disrupts a potential GATA-1 site. This suggests that lower hsa-miR-125a levels in the T/C and C/C variants, compared with the T/T variant, may be explained by diminished MIR125A transcription. According to the data of Hu et al, the fragment may potentially interact with undetermined nuclear proteins. The mechanism of the rs12976445 variant's effect on the level of MIR125A remains undetermined and it is unknown whether it is the transcriptional regulation effect, maturation of hsa-miR-125a effect or transport of hsa-miR-125a. The obstructed processing hypothesis is supported by the observation that Drosha-mediated maturation of pri-miR-125a is inhibited by p68/p72-dependent mechanisms upon stimulation of ERα (8) . We suggest that the rs12976445 variant may also reduce Drosha-mediated maturation, by disrupting the Drosha interaction with pri-miRNA. No correlation was observed between rs12976445 (T/T vs. T/C and C/C variants) and ESR1 mRNA levels in the present samples, however it may be that estrogens increase the effect of the variant, resulting in a hsa-miR-125a drop. It may be a matter of considerable interest to measure the estradiol levels in tumor samples.
There are three other known SNP variants in the amplified fragment containing has-miR-125a: rs10404453, rs12975333 and rs143525573 (11) . None of these variants were present in our samples. As determined by Li et al, the rs12975333 (variant T/C) is rare and is observed in only 8% of investigated breast cancers while it was absent in controls (11) . In the present study rs12976445 (variants T/C and C/C) was observed in 69.2% of tumors and in all the corresponding blood samples, where available. From this we deduced that rs12976445 is not a somatic tumor-origin mutation (11) . We concluded that the SNP rs12976445 in pri-miRNA may be an example of robustness in miRNA evolution (14) since the frequent genetic variant of this sequence does not cause marked phenotypic effects. Duan et al reported that rs12975333, in a +8-bp hairpin region of mature hsa-miR-125a, alters the processing of miRNA (10) . The hairpin region of miRNAs appears to be more conservative than the pri-miRNA flanking regions and, therefore, no rs12975333 variants of hsa-mir-125a was detected in the present small-scale study (n=26) and a very low frequency was described by Li et al in larger group (n=72) (11).
The correlation between rs12976445 and the risk of breast cancer remains to be confirmed. There may be several possible explanations for the robustness of the cell in spite of deregulated expression of MIR125A. The first explanation originates from observations of miRNA gene knockouts. Regardless of the large number of target genes predicted to be affected by miRNA, a complete loss of function in gene-knockout experiments for individual miRNAs has yielded no change in phenotype (15) . The functional redundancy of miRNA is postulated as a possible explanation for the phenomenon (15) . The second explanation is based on the hypothesis that certain genetic variations associated with the rs12976445 variant, may compensate for the lower expression of MIR125A.
Changes in the expression pattern of an miRNA generate novel sets of signals, leading to the formation of novel regulatory circuits (16) . At present, the complete regulatory circuit, called a feedforward loop (FFL) and involving hsa-miR-125a, ERBB2 and a third unknown component closing the loop, concomitantly regulated by ERBB2 and regulating miR125, has yet to be described (15) . An elevated level of ERBB2 mRNA in the T/C and C/C variants in comparison with the T/T variant was observed in the present study. This effect may be a consequence of a decrease in the level of hsa-miR-125a, which promotes ERBB2 mRNA decay and inhibits translation (1). The increase of ERBB2 transcript in tumors with the T/C and C/C variants was specific since neither a positive or a negative correlation was observed for the ESR1 and PGR transcripts. The patients with the T/C and C/C variants may potentially respond better to trastuzumab, though this response would need to be verified further in future studies. The level of the ERBB2 transcript correlated with the HER2 protein levels measured by immunohistochemical methods. Independently of the unconfirmed and possibly low, correlation between the rs12976445 variant and breast cancer risk, an awareness of miR-SNPs in the patient genome may allow oncologists to predict whether the patient is likely to respond to anti-HER2 chemotherapeutic drugs (17) .
